Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03620890 · ClinicalTrials.gov registry record · Phase 4

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 4
Development phase
108
Enrollment target

NCT03620890: Completed Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.

NCT03620890 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 108 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03620890, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 4
Development phase
108 participants
Enrollment target

Study Summary

To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).

Primary Outcome

Composite Adverse Neonatal Outcome includes 1 or more of any of the following: * Neonatal intensive care unit (NICU) admission or * Neonatal hypoglycemia (\<40 mg/dL in the first 24 hours of life and less than 50 mg/dL after) or requiring medical therapy or * Respiratory distress (need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life or * Shoulder dystocia - defined as the need for any extra ma

Interventions

  • DRUG Neutral Protamine Hagedorn (NPH)
  • DRUG Detemir insulin

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2018-09-04
Est. Completion 2020-07-29
Phase Phase 4

What the finished NCT03620890 record still lists

NCT03620890 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Neutral Protamine Hagedorn (NPH) is the first listed.

NCT03620890 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03620890 about?

NCT03620890 is a clinical study titled "Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy". To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).

What is the current status of trial NCT03620890?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2018-09-04. Estimated completion is 2020-07-29.

What interventions are being tested in trial NCT03620890?

The interventions under investigation include: Neutral Protamine Hagedorn (NPH) (DRUG), Detemir insulin (DRUG).

Who is sponsoring clinical trial NCT03620890?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03620890's enrollment target sits among peer trials

108 740th of 2000 higher than 1,256 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03620890, the US trial registry maintained by the National Library of Medicine. NCT03620890 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.